ENTO — Entero Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.73m
- $1.57m
- 10
- 59
- 27
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.03 | ||
| Price to Tang. Book | 0.03 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27% | ||
| Return on Equity | -51.66% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The Company is focused on developing the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis (CF) and chronic pancreatitis (CP) patients with exocrine pancreatic insufficiency (EPI). Adrulipase is the active pharmaceutical ingredient (API) derived from Yarrowia lipolytica, an aerobic yeast naturally found in various foods such as cheese and olive oil that is widely used as a biocatalyst in several industrial processes. The Company is developing Adrulipase for two principal therapeutic indications: children and adults affected by CF, and adult patients with CP.
Directors
- James Sapirstein CHM (60)
- Daniel Schneiderman CFO (40)
- James Pennington OTH (78)
- Edward Borkowski LED (60)
- Terry Coelho DRC (60)
- Charles Casamento IND (75)
- Gregory Oakes IND (52)
- Alastair Riddell IND (71)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 30th, 2014
- Public Since
- October 11th, 2016
- No. of Shareholders
- 85
- No. of Employees
- 2
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 4,765,729
- Address
- 777 Yamato Road, Suite 502, BOCA RATON, 33431
- Web
- https://enterothera.com/
- Phone
- +1 5615897020
- Auditors
- Mazars USA LLP
Upcoming Events for ENTO
Entero Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Entero Therapeutics Inc Earnings Release
Similar to ENTO
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Entero Therapeutics share price?
As of Today at 20:29 UTC, shares in Entero Therapeutics are trading at $0.36. This share price information is delayed by 15 minutes.
How has the Entero Therapeutics share price performed this year?
Shares in Entero Therapeutics last closed at $0.36 and the price had moved by -86.95% over the past 365 days. In terms of relative price strength the Entero Therapeutics share price has underperformed the S&P500 Index by -88.24% over the past year.
What are the analyst and broker recommendations for Entero Therapeutics?
The overall consensus recommendation for Entero Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Entero Therapeutics dividend yield?
Entero Therapeutics does not currently pay a dividend.
Does Entero Therapeutics pay a dividend?
Entero Therapeutics does not currently pay a dividend.
When does Entero Therapeutics next pay dividends?
Entero Therapeutics does not currently pay a dividend.
How do I buy Entero Therapeutics shares?
To buy shares in Entero Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Entero Therapeutics?
As of the previous close price of $0.36, shares in Entero Therapeutics had a market capitalisation of $1.73m.
Where are Entero Therapeutics shares listed?
Here are the trading details for Entero Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENTO
What kind of share is Entero Therapeutics?
Based on an overall assessment of its quality, value and momentum Entero Therapeutics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Entero Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Entero Therapeutics is $36.00. That is 9790.11% above the last closing price of $0.36.
Analysts covering Entero Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.52 for the next financial year.
Find out moreWhat is the trend in the Entero Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Entero Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -46.85%.
As of the last closing price of $0.36, shares in Entero Therapeutics were trading -29.59% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Entero Therapeutics PE Ratio?
The Entero Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Entero Therapeutics?
Entero Therapeutics' management team is headed by:
- James Sapirstein - CHM
- Daniel Schneiderman - CFO
- James Pennington - OTH
- Edward Borkowski - LED
- Terry Coelho - DRC
- Charles Casamento - IND
- Gregory Oakes - IND
- Alastair Riddell - IND